{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:10:32Z","timestamp":1790302232594,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune-mediated necrotizing myopathy (IMNM) is a subgroup of idiopathic inflammatory myopathies associated with anti-signal recognition particle (SRP) or anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies. The direct pathogenic effects of IMNM patient autoantibodies on skeletal muscle contractile force, independent of the downstream activation of the complement pathway, remain understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study leverages a custom 3-D human skeletal muscle microtissue (hMMT) culture platform that encourages muscle cell contractile apparatus maturation and enables analysis of contractile function. Force generation competent hMMTs were treated with total immunoglobulins (IgGs) isolated from the plasma of IMNM patients with amplification of anti-SRP\n                      <jats:sup>+<\/jats:sup>\n                      (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097) or anti-HMGCR\n                      <jats:sup>+<\/jats:sup>\n                      (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097) autoantibodies and delivered in complement inactivated media for 4 days. hMMT function was then evaluated by quantifying the peak force and contraction kinetics in response to electrical field stimulation, followed by histological analysis of muscle cell gross morphology and sarcomere structure. To determine whether IgG from IMNM patients can enter muscle cells, 2-D myotube cultures were treated with donor total IgG delivered in complement replete media for 36\u00a0h, and then analyzed using immunostaining and confocal microscopy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Exposure to total IgGs isolated from a subset of IMNM patients induced a decline in hMMT twitch and tetanus contractile force and were associated with sarcomere fragility and slowed muscle cell contraction and relaxation rates. Pathogenic influences on hMMT force generation were observed at a greater frequency in response to total IgGs isolated from IMNM patients with anti-HMGCR\u2009+\u2009autoantibodies. Substantial intracellular human IgG staining was observed in conditions where myotubes were treated with total IgGs from IMNM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates that total IgGs isolated from IMNM patients have the aberrant capacity to enter muscle cells in the absence of complement. Further, a subset of patient IgGs exert direct pathogenic influences on engineered muscle contractile function that are independent of the complement system. Together, these findings have important implications for the advancement of IMNM precision medicine therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13395-025-00400-7","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:44:56Z","timestamp":1764031496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Complement-independent pathogenic influences of anti-HMGCR\u2009+\u2009and anti-SRP\u2009+\u2009immune-mediated necrotizing myopathy autoantibodies on engineered muscle function"],"prefix":"10.1186","volume":"16","author":[{"given":"Heta","family":"Lad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yekaterina","family":"Tiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest Myguel","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandrine","family":"Mahoudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoye","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Tendrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penney M.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"400_CR1","doi-asserted-by":"crossref","unstructured":"Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021;51(6):845\u201352.","DOI":"10.1111\/imj.15358"},{"key":"400_CR2","doi-asserted-by":"crossref","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers [Internet]. 2021 Dec 2 [cited 2022 Nov 13];7(1):1\u201322. Available from: https:\/\/www.nature.com\/articles\/s41572-021-00321-x.","DOI":"10.1038\/s41572-021-00321-x"},{"issue":"2","key":"400_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102993","volume":"21","author":"G Merlonghi","year":"2022","unstructured":"Merlonghi G, Antonini G, Garibaldi M. Immune-mediated necrotizing myopathy (IMNM): a myopathological challenge. Autoimmun Rev. 2022;21(2):102993.","journal-title":"Autoimmun Rev"},{"key":"400_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113936","volume":"156","author":"R Qiu","year":"2022","unstructured":"Qiu R, Wang Z, Wei X, Sui H, Jiang Z, Yu XF. The pathogenesis of anti-signal recognition particle necrotizing myopathy: a review. Biomed Pharmacother. 2022;156:113936.","journal-title":"Biomed Pharmacother"},{"key":"400_CR5","doi-asserted-by":"crossref","unstructured":"Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol [Internet]. 2020 Dec [cited 2022 Nov 16];16(12):689\u2013701. Available from: https:\/\/www.nature.com\/articles\/s41584-020-00515-9.","DOI":"10.1038\/s41584-020-00515-9"},{"key":"400_CR6","doi-asserted-by":"crossref","unstructured":"Miller T, Al-Lozi M, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry [Internet]. 2002 Oct [cited 2025 Mar 30];73(4):420\u20138. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1738058\/.","DOI":"10.1136\/jnnp.73.4.420"},{"issue":"4 Pt 2","key":"400_CR7","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/j.lpm.2010.11.023","volume":"40","author":"O Benveniste","year":"2011","unstructured":"Benveniste O, Romero NB. Myositis or dystrophy? Traps and pitfalls. Presse Med. 2011;40(4 Pt 2):e249\u2013255.","journal-title":"Presse Med"},{"issue":"12","key":"400_CR8","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1002\/art.34673","volume":"64","author":"JL Werner","year":"2012","unstructured":"Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087\u201393.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"400_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC international workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, the Netherlands, 14\u201316 October 2016. Neuromuscul Disord. 2018;28(1):87\u201399.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"400_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MD.0000000000000028","volume":"93","author":"Y Allenbach","year":"2014","unstructured":"Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore). 2014;93(3):150\u20137.","journal-title":"Medicine (Baltimore)"},{"key":"400_CR11","doi-asserted-by":"publisher","unstructured":"Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A et al. Correlation of anti\u2013signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis & Rheumatism [Internet]. 2011 [cited 2025 Mar 30];63(7):1961\u201371. Available from:\u00a0https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/art.30344.","DOI":"10.1002\/art.30344"},{"issue":"6","key":"400_CR12","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","volume":"90","author":"Y Allenbach","year":"2018","unstructured":"Allenbach Y, Arouche-Delaperche L, Preusse C, Radbruch H, Butler-Browne G, Champtiaux N, et al. Necrosis in anti-SRP\u2009+\u2009and anti-HMGCR\u2009+\u2009myopathies: role of autoantibodies and complement. Neurology. 2018;90(6):e507-17.","journal-title":"Neurology"},{"key":"400_CR13","doi-asserted-by":"publisher","unstructured":"Arouche-Delaperche L, Allenbach Y, Amelin D, Preusse C, Mouly V, Mauhin W et al. Pathogenic role of anti\u2013signal recognition protein and anti\u20133-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Annals of Neurology [Internet]. 2017 [cited 2022 Nov 16];81(4):538\u201348. Available from:\u00a0https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/ana.24902.","DOI":"10.1002\/ana.24902"},{"issue":"1","key":"400_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","volume":"78","author":"C Bergua","year":"2019","unstructured":"Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78(1):131\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213518.","journal-title":"Ann Rheum Dis"},{"key":"400_CR15","doi-asserted-by":"crossref","unstructured":"Mammen AL, Amato AA, Dimachkie MM, Chinoy H, Hussain Y, Lilleker JB et al. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol [Internet]. 2023 Feb 1 [cited 2025 Mar 30];5(2):e67\u201376. Available from: https:\/\/europepmc.org\/articles\/PMC10009502.","DOI":"10.1016\/S2665-9913(23)00003-6"},{"issue":"8","key":"400_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082036","volume":"10","author":"S Julien","year":"2022","unstructured":"Julien S, Vadysirisack D, Sayegh C, Ragunathan S, Tang Y, Briand E, et al. Prevention of anti-HMGCR immune-mediated necrotising myopathy by C5 complement inhibition in a humanised mouse model. Biomedicines. 2022;10(8):2036.","journal-title":"Biomedicines"},{"issue":"12","key":"400_CR17","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","volume":"62","author":"S Julien","year":"2023","unstructured":"Julien S, van der Woning B, De Ceuninck L, Briand E, Jaworski T, Roussel G, et al. Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy. Rheumatology (Oxford). 2023;62(12):4006\u201311.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"400_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/ard-2022-223541","volume":"82","author":"O Landon-Cardinal","year":"2023","unstructured":"Landon-Cardinal O, Allard-Chamard H, Chapdelaine H, Doucet S, Rich \u00c9, Bourr\u00e9-Tessier J. Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy. Ann Rheum Dis. 2023;82(4):579\u201380.","journal-title":"Ann Rheum Dis"},{"key":"400_CR19","doi-asserted-by":"crossref","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890\u2013e49049.","DOI":"10.1016\/j.cell.2024.06.027"},{"issue":"11","key":"400_CR20","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","volume":"32","author":"J Volkov","year":"2024","unstructured":"Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z, et al. Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial. Mol Ther. 2024;32(11):3821\u20138.","journal-title":"Mol Ther"},{"issue":"7","key":"400_CR21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217831120","volume":"120","author":"Y Yogev","year":"2023","unstructured":"Yogev Y, Shorer Z, Koifman A, Wormser O, Drabkin M, Halperin D. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc Natl Acad Sci USA. 2023;120(7):e2217831120.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"400_CR22","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/ard-2024-225773","volume":"83","author":"I Pinal-Fernandez","year":"2024","unstructured":"Pinal-Fernandez I, Mu\u00f1oz-Braceras S, Casal-Dominguez M, Pak K, Torres-Ruiz J, Musai J, et al. Pathological autoantibody internalisation in myositis. Ann Rheum Dis. 2024;83(11):1549\u201360.","journal-title":"Ann Rheum Dis"},{"key":"400_CR23","doi-asserted-by":"crossref","unstructured":"Giannini et al. In immune-mediated necrotizing myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis. Ann Rheum Dis. 2025;84:1752\u201355. https:\/\/doi.org\/10.1016\/j.ard.2025.04.027.","DOI":"10.1016\/j.ard.2025.04.027"},{"key":"400_CR24","doi-asserted-by":"crossref","unstructured":"Afshar ME, Abraha HY, Bakooshli MA, Davoudi S, Thavandiran N, Tung K et al. A 96-well culture platform enables longitudinal analyses of engineered human skeletal muscle microtissue strength. Sci Rep [Internet]. 2020 Apr 24 [cited 2022 Nov 13];10(1):6918. Available from: https:\/\/www.nature.com\/articles\/s41598-020-62837-8.","DOI":"10.1038\/s41598-020-62837-8"},{"key":"400_CR25","doi-asserted-by":"crossref","unstructured":"Ebrahimi M, Lad H, Fusto A, Tiper Y, Datye A, Nguyen CT et al. De novo revertant fiber formation and therapy testing in a 3D culture model of Duchenne muscular dystrophy skeletal muscle. Acta Biomaterialia [Internet]. 2021 Sept 15 [cited 2023 Mar 22];132:227\u201344. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1742706121003305.","DOI":"10.1016\/j.actbio.2021.05.020"},{"key":"400_CR26","doi-asserted-by":"crossref","unstructured":"Lad H, Musgrave B, Ebrahimi M, Gilbert PM. Assessing functional metrics of skeletal muscle health in human skeletal muscle microtissues. J Vis Exp. 2021;(168).","DOI":"10.3791\/62307"},{"key":"400_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-1-34","volume":"1","author":"K Mamchaoui","year":"2011","unstructured":"Mamchaoui K, Trollet C, Bigot A, Negroni E, Chaouch S, Wolff A, et al. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle. 2011;1:34.","journal-title":"Skelet Muscle"},{"issue":"4","key":"400_CR28","doi-asserted-by":"publisher","first-page":"C1160","DOI":"10.1152\/ajpcell.00308.2024","volume":"328","author":"Y Tiper","year":"2025","unstructured":"Tiper Y, Xie Z, Hofemeier A, Lad H, Luber M, Krawetz R, et al. Optimizing electrical field stimulation parameters reveals the maximum contractile function of human skeletal muscle microtissues. Am J Physiol Cell Physiol. 2025;328(4):C1160\u201376.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"400_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s44330-024-00005-4","volume":"1","author":"N Gulati","year":"2024","unstructured":"Gulati N, Davoudi S, Xu B, Rjaibi ST, Jacques E, Pham J, et al. Mini-MEndR: a miniaturized 96-well predictive assay to evaluate muscle stem cell-mediated repair. BMC Methods. 2024;1(1):5.","journal-title":"BMC Methods"},{"key":"400_CR30","doi-asserted-by":"publisher","unstructured":"Tiper Y, Ni J, Krawetz R, Gilbert PM. Elevated GLUT4 Levels in Human Skeletal Muscle Microtissues is Accompanied by Functional Insulin Dependence [Internet]. Cell Biology; 2025 [cited 2025 Aug 20]. Available from:\u00a0http:\/\/biorxiv.org\/lookup\/doi\/https:\/\/doi.org\/10.1101\/2025.04.24.650438.","DOI":"10.1101\/2025.04.24.650438"},{"issue":"3","key":"400_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007676","volume":"16","author":"TA Morris","year":"2020","unstructured":"Morris TA, Naik J, Fibben KS, Kong X, Kiyono T, Yokomori K, et al. Striated myocyte structural integrity: automated analysis of sarcomeric z-discs. PLoS Comput Biol. 2020;16(3):e1007676.","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"400_CR32","doi-asserted-by":"publisher","first-page":"C749","DOI":"10.1152\/ajpcell.00049.2021","volume":"321","author":"CT Nguyen","year":"2021","unstructured":"Nguyen CT, Ebrahimi M, Gilbert PM, Stewart BA. Electrophysiological analysis of healthy and dystrophic 3-D bioengineered skeletal muscle tissues. Am J Physiol Cell Physiol. 2021;321(4):C749-59.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"8","key":"400_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR t-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"issue":"6","key":"400_CR34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121","volume":"121","author":"C Qin","year":"2024","unstructured":"Qin C, Dong MH, Zhou LQ, Wang W, Cai SB, You YF, et al. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc Natl Acad Sci U S A. 2024;121(6):e2315990121. https:\/\/doi.org\/10.1073\/pnas.2315990121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"400_CR35","doi-asserted-by":"crossref","unstructured":"Moyle LA, Jacques E, Gilbert PM. Engineering the next generation of human skeletal muscle models: From cellular complexity to disease modeling. Current Opinion in Biomedical Engineering [Internet]. 2020 Dec [cited 2025 Aug 18];16:9\u201318. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468451120300222.","DOI":"10.1016\/j.cobme.2020.05.006"},{"issue":"1","key":"400_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-13-74","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Nelson DR, Zhao Y, Cui Z, Johnston JA. Relationship between muscle mass and muscle strength, and the impact of comorbidities: a population-based, cross-sectional study of older adults in the United States. BMC Geriatr. 2013;13(1):74. https:\/\/doi.org\/10.1186\/1471-2318-13-74.","journal-title":"BMC Geriatr"},{"key":"400_CR37","doi-asserted-by":"crossref","unstructured":"Reggiani C, Schiaffino S. Muscle hypertrophy and muscle strength: dependent or independent variables? A provocative review. Eur J Transl Myol [Internet]. 2020 Sept 9 [cited 2025 Mar 30];30(3):9311. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7582410\/.","DOI":"10.4081\/ejtm.2020.9311"},{"issue":"1","key":"400_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-018-2008-8","volume":"19","author":"T Nawata","year":"2018","unstructured":"Nawata T, Kubo M, Nomura T, Oishi K, Shiragami K, Ikegami T, et al. Change in muscle volume after steroid therapy in patients with myositis assessed using cross-sectional computed tomography. BMC Musculoskelet Disord. 2018;19(1):93.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"400_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00441-024-03864-z","volume":"396","author":"CT Nguyen","year":"2024","unstructured":"Nguyen CT, Ch\u00e1vez-Madero C, Jacques E, Musgrave B, Yin T, Saraci K, et al. Electron microscopic analysis of the influence of iPSC-derived motor neurons on bioengineered human skeletal muscle tissues. Cell Tissue Res. 2024;396(1):57\u201369.","journal-title":"Cell Tissue Res"},{"key":"400_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.44530","volume":"8","author":"M Afshar Bakooshli","year":"2019","unstructured":"Afshar Bakooshli M, Lippmann ES, Mulcahy B, Iyer N, Nguyen CT, Tung K, et al. A 3D culture model of innervated human skeletal muscle enables studies of the adult neuromuscular junction. Elife. 2019;8:e44530.","journal-title":"Elife"},{"key":"400_CR41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.04885","volume":"4","author":"L Madden","year":"2015","unstructured":"Madden L, Juhas M, Kraus WE, Truskey GA, Bursac N. Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs. Elife. 2015;4:e04885.","journal-title":"Elife"},{"key":"400_CR42","doi-asserted-by":"crossref","unstructured":"Chen TW, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A et al. Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature [Internet]. 2013 July [cited 2025 Mar 30];499(7458):295\u2013300. Available from: https:\/\/www.nature.com\/articles\/nature12354.","DOI":"10.1038\/nature12354"}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-025-00400-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13395-025-00400-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-025-00400-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:28:02Z","timestamp":1770391682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13395-025-00400-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1186\/s13395-025-00400-7","relation":{},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IMNM patient plasma was collected during plasmapheresis and stored in our biobank MASC (Myositis, DNA, Serum, Cells, ClinicalTrials.gov Identifier: NCT04637672). Approvals by the Local Ethics Committee (CPP Ile De France VI (2013-12-19), CCTIRS (N\u00b014.323) and CNIL (915139)) were obtained to conduct the studies described herein. Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This work was supported in part by a sponsored research agreement between P.M.G. and RA Pharma (acquired by UCB).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}